Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
1,429,315 | 1,394,467 | 1,322,541 | 1,254,232 | 1,276,097 |
Cost of Goods Sold (COGS) incl. D&A |
142,564 | 120,779 | 116,000 | 114,280 | 152,548 |
COGS excluding D&A |
51,992 | 52,961 | 51,533 | 53,690 | 58,709 |
Depreciation & Amortization Expense |
90,572 | 67,818 | 64,467 | 60,590 | 93,839 |
Gross Income |
1,286,751 | 1,273,688 | 1,206,541 | 1,139,952 | 1,123,549 |
SG&A Expense |
843,511 | 796,239 | 770,125 | 665,670 | 751,534 |
Research & Development |
473,419 | 441,595 | 447,098 | 339,892 | 436,427 |
Other SG&A |
370,092 | 354,644 | 323,027 | 325,778 | 315,107 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
114,956 | -2,680 | -32,466 | -91 | -87,320 |
Non Operating Income/Expense |
-19,677 | 12,923 | -19,832 | 6,119 | -42,626 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 1,187 | 0 |
Interest Expense |
24,003 | 19,295 | 11,474 | 11,385 | 11,277 |
Gross Interest Expense |
24,003 | 19,295 | 11,474 | 11,385 | 11,277 |
Pretax Income |
290,303 | 476,502 | 440,684 | 474,002 | 405,432 |
Income Tax |
27,188 | 52,347 | 73,311 | 72,465 | -8,516 |
Equity in Affiliates |
0 | 0 | 0 | 0 | -3,770 |
Consolidated Net Income |
263,115 | 424,155 | 367,373 | 401,537 | 410,178 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
263,115 | 424,155 | 367,373 | 401,537 | 410,178 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | NA | NA | 0 |
Net Income After Extraordinaries |
263,115 | 424,155 | 367,372 | 401,536 | 410,177 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
263,115 | 424,155 | 367,373 | 401,537 | 410,178 |
Operational EPS |
0.78 | 0.97 | 0.77 | 0.89 | 0.75 |
EPS (basic) |
0.62 | 0.99 | 0.84 | 0.92 | 0.90 |
EBITDA |
533,812 | 545,267 | 500,883 | 534,872 | 465,854 |
Depreciation & Amortization Expense |
90,572 | 67,818 | 64,467 | 60,590 | 93,839 |
Common Shares Outstanding |
440,796 | 436,272 | 445,379 | 448,598 | 462,748 |
Basic Shares Outstanding |
430,927 | 427,209 | 436,703 | 438,349 | 455,348 |
Diluted Shares Outstanding |
440,796 | 436,272 | 445,379 | 448,598 | 462,748 |
Diluted EPS after Extraordinary Items |
0.60 | 0.97 | 0.82 | 0.90 | 0.89 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.61 | 0.99 | 0.84 | 0.92 | 0.89 |
*Figures in thousands of U.S. Dollars except shares outstanding.
